OECD Health Working Papers

ISSN :
1815-2015 (online)
DOI :
10.1787/18152015
Hide / Show Abstract
This series is designed to make available to a wider readership health studies prepared for use within the OECD. Authorship is usually collective, but principal writers are named. The papers are generally available only in their original language - English or French - with a summary in the other.
 

Pharmaceutical Pricing and Reimbursement Policies in Germany You or your institution have access to this content

Click to Access: 
    http://oecd.metastore.ingenta.com/content/5ksqczrw7jjj.pdf
  • PDF
  • http://www.keepeek.com/Digital-Asset-Management/oecd/social-issues-migration-health/pharmaceutical-pricing-and-reimbursement-policies-in-germany_228483137521
  • READ
Author(s):
Valérie Paris1, Elizabeth Docteur
Author Affiliations
  • 1: OECD, France

Publication Date
21 Oct 2008
Bibliographic information
No.:
39
Pages
66
DOI
10.1787/228483137521

Hide / Show Abstract

This paper describes pharmaceutical pricing and reimbursement policies in Germany, considering them in the broader environment in which they operate, and assesses their impact on the achievement of a number of policy goals. Pharmaceutical coverage is comprehensive, with a high level of public funding, and ensures access to treatments. However, recent increases in out-of-pocket payments may impair affordability for the poorest part of the population. Germany does not regulate ex-manufacturer prices of pharmaceuticals at market entry (though distribution margins are regulated for reimbursed drugs). On the other hand, maximum reimbursement amounts (known as reference prices) are set for products which can be clustered in groups of equivalent (generic) or comparable products (...)
JEL Classification:
  • I11: Health, Education, and Welfare / Health / Analysis of Health Care Markets
  • I18: Health, Education, and Welfare / Health / Government Policy; Regulation; Public Health